Mutual interaction between remacemide hydrochloride and carbamazepine: Two drugs with active metabolites

Epilepsia

Volumn 37, Issue 11, 1996, Pages 1100-1106

  Leach, John Paul ^a   Blacklaw, Jackie ^a   Jamieson, Virginia ^b   Jones, Tracey ^b   Richens, Alan ^c   Brodie, Martin J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Carbamazepine; Drug interaction; Epilepsy; Remacemide hydrochloride

Indexed keywords

1 METHYL 1,2 DIPHENYLETHYLAMINE; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; PLACEBO; REMACEMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG METABOLISM; DRUG SCREENING; EPILEPSY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029843239     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb01031.x     Document Type: Article

References (26)

1. Palmer GC, Harris EW, Ray R, Stagnitto ML, Schmiesing RJ. Classification of compounds for prevention of NMDA-induced seizures/mortality, or maximal electroshock and pentylenetetrazol seizures in mice and antagonism of MK801 binding in vitro. Arch Int Pharmacodyn Ther 1992;317:16-34.
2. Heyn H, McCarthy DJ, Curry SH, Eisman MS, Anders MW. Brian uptake and biotransformation of remacemide hydrochloride, a novel anticonvulsant. Drug Metab Dispos 1994;22:443-6.
3. Muir KT, Palmer GC. Remacemide. Epilepsy Res 1991;10(suppl 3):147-56.
4. Palmer GC, Murray RJ, Wilson TC, et al. Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide. Epilepsy Res 1992;12:9-20.
5. Garske GE, Palmer GC, Napier JJ, et al. Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat. Epilepsy Res 1991;9:161-74.
6. Palmer GC, Clark B, Hutchison JB. Antiepileptic and neuroprotective potential of remacemide hydrochloride. Drugs Future 1993;18:1021-42.
7. Bannan PE, Graham DI, Lees KR, McCulloch J. Neuroprotective effect of remacemide hydrochloride in focal cerebral ischaemia in the cat. Brain Res 1994;664:271-5.
8. Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R, Gash DM. Aniiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 1994;35:655-61.
9. Brodie MJ, Dichter MA. Established antiepileptic drugs. N Engl J Med 1996;334:168-75.
10. Macphee GJA, Butler E, Brodie MJ. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism. Epilepsia 1987;28:286-94.
11. Brodie MJ. Drug interactions and epilepsy. Epilepsia 1992;33: S13-22.
12. Gillham RA, Williams N, Weidmann K, Butler E, Larkin JG, Brodie MJ. Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients. J Neurol Neurosurg Psychiatry 1988;51:929-33.
13. Brodie MJ, Forrest G, Rappeport WG. Carbamazepine 10,11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants. Br J Clin Pharmacol 1983;16:747-50.
14. McKee PJW. Brodie MJ. Pharmacokinetic interactions with anti-epileptic drugs. In: Chichester: John Wiley, Trimble MR, ed. New anticonvulsants: advances in the treatment of epilepsy. 1994:1-33.
15. McKee PJW, Blacklaw J, Forrest G, et al. A double-blind, placebo controlled interaction study between oxcarbazepine, carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994;37:27-32.
16. Flynn JW, O'Brien J. High performance liquid Chromatographic method for the simultaneous measurement of remacemide (a novel anticonvulsant and cerebroprotectant) and an active metabolite in human plasma. J Chromatog 1992;583:91-7.
17. Eichelbaum M, Tomson T, Tybring G, Bertilsson L. Carbamazepine metabolism in man: induction and pharmacogenic aspects. Clin Pharmacokinet 1985;10:80-90.
18. Macphee GJA, Mitchell J, Wiseman L, et al. Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man. Br J Clin Pharmacol 1988;25:59-66.
19. McKee PJW, Blacklaw J, Butler E, Gillham RA, Brodie MJ. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res 1992;11:193-8.
20. Clark B, Hutchinson JB, Jamieson V, Jones T, Palmer GC, Scheyer RD. Potential antiepileptic drugs: remacemide hydrochloride. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs 4th ed. New York: Raven Press, 1995:1035-44.
21. Faigle JW, Feldman KF. Carbamazepine. Chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs 4th ed. New York: Raven Press, 1995:499-513.
22. Brodie MJ, Forrest G, Rapeport WG. Carbamazepine 10,11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants. Br J Clin Pharmacol 1983;16:747-50.
23. Westenberg HGM, Van der Kleijn E, Oei TT, der Zeeuw RA. Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva. Clin Pharmacol Ther 1978; 23:320-8.
24. Monaco F, Riccio A, Fantini M, Baruzzi A, Morselli PL. A month by month long-term study on carbamazepine: clinical, EEG and pharmacological evaluation. J Int Med Res 1979;7:152-7.
25. Levy RH, Warden CJ. Carbamazepine. Interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs 4th ed. New York: Raven Press, 1995:543-54.
26. Macphee GJA, Butler E, Brodie MJ. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of auto-induction of metabolism. Epilepsia 1987;28:286-94.